Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
258 studies found for:    209as209
Show Display Options
Rank Status Study
1 Terminated Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: STX209 (arbaclofen)
2 Completed Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
Condition: Hypercholesterolemia
Interventions: Drug: LGT209;   Drug: Placebo
3 Completed Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins
Conditions: Hypercholesterolemia,;   LDL Cholesterol
Interventions: Drug: LGT209 50 mg;   Drug: LGT209 300 mg;   Drug: Placebo;   Drug: Statins (atorvastatin or simvastatin)
4 Recruiting Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Condition: Viral Conjunctivitis
Interventions: Drug: APD-209 Eye drops;   Drug: APD-209 Placebo Eye drops
5 Not yet recruiting Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: MOR209/ES414
6 Recruiting MEG Study of STX209
Condition: Autism Disorder
Interventions: Drug: STX209;   Drug: placebo
7 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: Placebo
8 Completed
Has Results
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: STX209;   Drug: Placebo
9 Terminated An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: arbaclofen
10 Completed Pilot Study of APD209 in Cancer Cachexia
Condition: Cancer-related Cachexia
Intervention: Drug: APD209
11 Terminated An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: Arbaclofen
12 Completed Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
Condition: Fragile X Syndrome
Interventions: Drug: arbaclofen;   Drug: placebo
13 Completed
Has Results
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
14 Completed Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma
Interventions: Biological: HPV 16 E7:12-20 peptide vaccine;   Biological: gp100:209-217(210M) peptide vaccine;   Other: laboratory biomarker analysis
15 Completed Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100:209-217(210M) peptide vaccine;   Biological: HPV 16 E7:12-20 peptide vaccine;   Other: laboratory biomarker analysis
16 Terminated An Open Label Extension Study in Subjects With Fragile X Syndrome
Condition: Fragile X Syndrome
Intervention: Drug: arbaclofen
17 Completed Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Biological: aldesleukin;   Biological: gp100:209-217(210M) peptide vaccine;   Other: laboratory biomarker analysis
18 Completed
Has Results
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
Condition: High-Risk Melanoma
Interventions: Drug: gp100:209-217 (210M);   Drug: Montanide ISA-51;   Drug: Imiquimod
19 Completed Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Condition: Autism Spectrum Disorders
Intervention: Drug: Arbaclofen
20 Completed Biomarker and DNA Collection in Subjects Participating in Protocol 22003
Condition: Fragile X Syndrome
Intervention: Drug: STX209

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years